文献速递淋巴瘤造血干细胞移植与细胞治疗

大B细胞淋巴瘤患者接受阿基仑赛治疗时早期使用糖皮质激素管理不良事件

Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
PubMed 文献 · Br J Haematol · 2021-09-29

ZUMA-1研究第4队列评估了复发或难治性大B细胞淋巴瘤患者接受阿基仑赛后早期使用糖皮质激素和托珠单抗的安全性。

要点

  • 早期使用糖皮质激素和托珠单抗可能降低≥3级CRS和NE发生率
  • 任何级别CRS发生率93%,≥3级仅2%;任何级别NE发生率61%,≥3级17%

核心结论

  • 早期且适度使用糖皮质激素和/或托珠单抗可能降低接受阿基仑赛的复发或难治性大B细胞淋巴瘤患者≥3级细胞因子释放综合征和神经事件的发生率。

研究设计与样本

  • ZUMA-1(NCT02348216)是在难治性大B细胞淋巴瘤中开展的关键1/2期研究,第4队列评估早期使用糖皮质激素和托珠单抗时细胞因子释放综合征和神经事件的发生率与严重程度。

主要发现

  • 任何级别细胞因子释放综合征和神经事件的发生率分别为93%和61%,≥3级分别为2%和17%。
  • 无4级或5级细胞因子释放综合征或神经事件。
  • 尽管早期给药,需要糖皮质激素治疗的患者累积皮质酮等效糖皮质激素剂量低于关键ZUMA-1队列所报告的剂量。

临床怎么用

  • 对于接受阿基仑赛的复发或难治性大B细胞淋巴瘤患者,可考虑早期且适度使用糖皮质激素和/或托珠单抗以降低≥3级细胞因子释放综合征和神经事件的发生率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed or refractory large B-cell lymphoma (R/R LBCL). To reduce axi-cel-related toxicity, several exploratory safety management cohorts were added to ZUMA-1 (NCT02348216), the pivotal phase 1/2 study of axi-cel in refractory LBCL. Cohort 4 evaluated the rates and severity of cytokine release syndrome (CRS) and neurologic events (NEs) with earlier corticosteroid and tocilizumab use. Primary endpoints were incidence and severity of CRS and NEs. Patients received 2 × 106 anti-CD19 CAR T cells/kg after conditioning chemotherapy. Forty-one patients received axi-cel. Incidences of any-grade CRS and NEs were 93% and 61%, respectively (grade ≥ 3, 2% and 17%). There was no grade 4 or 5 CRS or NE. Despite earlier dosing, the cumulative cortisone-equivalent corticosteroid dose in patients requiring corticosteroid therapy was lower than that reported in the pivotal ZUMA-1 cohorts. With a median follow-up of 14·8 months, objective and complete response rates were 73% and 51%, respectively, and 51% of treated patients were in ongoing response. Earlier and measured use of corticosteroids and/or tocilizumab has the potential to reduce the incidence of grade ≥ 3 CRS and NEs in patients with R/R LBCL receiving axi-cel.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Topp MS, van Meerten T, Houot R, et al. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021. PMID: 34590303. doi:10.1111/bjh.17673

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。